Today on Pharmaceutical Processing
Novo Nordisk to boost GLP-1 capacity with €2.1 billion investment in France
Novo Nordisk announced last week that it plans to invest approximately 16 billion Danish kroner €2.1 billion in GLP-1 drug production. The company plans to expand its Chartres, France, production site for its current and future product portfolio within serious chronic diseases. This investment significantly increases the capacity of the manufacturing site. It adds aseptic…
Biden’s supply chain plans include made-in-America medicines
The Biden administration recently announced efforts to strengthen the pharmaceutical supply chain, mitigate shortages of essential medicines, and expand domestic manufacturing. The new efforts are part of an overall package of initiatives to boost U.S. supply chains that the White Houe announced on Nov. 27. Securing the country’s supply of medicines and lowering prices have…
Sponsored Content See More >
Revolutionizing Pharma Sustainability: Grundfos Solutions for Optimizing EfficiencyThis white paper highlights the pressing need for sustainability in the pharmaceutical industry, where energy-intensive processes contribute significantly to environmental…
The Evolution of Heat Sealingby Charles H. Trillich / Co-Founder Packworld USA Heat sealing technology has evolved over many decades to reduce cost and…
Difficult transmembrane protein targets for therapeutic antibodiesWhat is the current landscape of antibodies targeting membrane proteins? As of June 2022, 162 antibodies had been approved for…
Validatable Band Sealers for Medical PouchesBy Lynn Miranda, Sales Manager for All Packaging Machinery Corp, Ronkonkoma, NY. The customer’s level of confidence and trust is…
Raumedic: A Trusted Partner in Serving the Pharmaceutical Industry with the Gold Standard in Silicone TubingRaumedic is a trusted partner in the international medical technology and pharmaceutical industry. The medical division of the global corporation…
A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…
Anti-idiotype Antibodies: A Powerful Weapon for PK/ADA AssaysBy Sino Biological Therapeutic monoclonal antibodies have emerged as the fastest-growing class of therapeutics since the mid-1980s from the increasing…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Regulatory See More >
Navigating the new regulatory terrain pharma companies face with IRA and 340B
The ever-evolving landscape of pharmaceutical regulations has long been challenging to navigate, but now pharma companies face additional complexities with the introduction of the Inflation Reduction Act (IRA) and the ongoing implementation of the 340B drug pricing program. In recent years, the IRA has made waves for its impact on the pharmaceutical industry, including proposals…
Facility See More >
Pfizer’s $3.5B cost-cutting strategy hits Peapack site in New Jersey
After news emerged regarding Pfizer’s plans to close sites in North Carolina, the company is adding New Jersey to the list. The company expects its Peapack facility to cease operations in early 2024. A Worker Adjustment and Retraining Notification(WARN) Notice notes that 791 workers could potentially be cut from its Somerset County corporate office. The…
Supply Chain See More >
Biden’s supply chain plans include made-in-America medicines
The Biden administration recently announced efforts to strengthen the pharmaceutical supply chain, mitigate shortages of essential medicines, and expand domestic manufacturing. The new efforts are part of an overall package of initiatives to boost U.S. supply chains that the White Houe announced on Nov. 27. Securing the country’s supply of medicines and lowering prices have…
Recalls See More >
PBMs increasingly under fire in drug-pricing battle
As the national debate over drug pricing ramps up, Pharmacy Benefit Managers (PBMs) find themselves squarely in the spotlight. PhRMA, which has also criticized hospitals for marking up drug prices by as much as 500%, launched a seven-figure ad campaign targeting proposals in Congress to lower drug prices. PhRMA, which counts companies such as Pfizer,…
